These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Taché Y; Martinez V; Million M; Maillot C Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists. Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437 [TBL] [Abstract][Full Text] [Related]
5. Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety. St-Denis Y; Di Fabio R; Bernasconi G; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Ghirlanda D; Marchionni C; Messina F; Micheli F; Pavone F; Pasquarello A; Sabbatini FM; Zampori MG; Arban R; Vitulli G Bioorg Med Chem Lett; 2005 Aug; 15(16):3713-6. PubMed ID: 15946843 [TBL] [Abstract][Full Text] [Related]
6. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists. Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489 [TBL] [Abstract][Full Text] [Related]
8. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436 [TBL] [Abstract][Full Text] [Related]
9. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210 [TBL] [Abstract][Full Text] [Related]
10. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? Nielsen DM Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists. Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists. Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists. Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983 [TBL] [Abstract][Full Text] [Related]
19. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Kehne J; De Lombaert S Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):467-93. PubMed ID: 12769601 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF₁ receptor antagonists. Takeda K; Terauchi T; Hashizume M; Shin K; Ino M; Shibata H; Yonaga M Bioorg Med Chem Lett; 2012 Sep; 22(17):5372-8. PubMed ID: 22871582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]